Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective studyBruyère, Olivier ; ; Nicolet, Delphine et alin Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 588 Detailed reference viewed: 11 (4 ULg) Severity of incident vertebral fracture and future fracture risk: a 3-year prospective studyBruyère, Olivier ; ; Nicolet, Delphine et alin Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 716 Detailed reference viewed: 17 (4 ULg) Severity of incident vertebral fracture and future fracture risk: a 3-year prospective studyBruyère, Olivier ; ; Nicolet, Delphine et alin Osteoporosis International (2012, March), 23(Suppl. 2), 60-61 Detailed reference viewed: 26 (9 ULg) Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective studyBruyère, Olivier ; ; Nicolet, Delphine et alin Osteoporosis International (2012, March), 23(Suppl. 2), 361-362 Detailed reference viewed: 13 (4 ULg) Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 yearsReginster, Jean-Yves ; ; et alin Osteoporosis International (2011, March), 22(Suppl.1), 110-111 Detailed reference viewed: 32 (6 ULg) Weekly alendronate plus vitamin D3 5,600 IU vs. standard care: effect on serum 25(OH) vitamin D, bone turnover markers, and BMD in osteoporotic postmenopausal women with vitamin D inadequacy - 1 year results of a randomized trialReginster, Jean-Yves ; ; et alin Osteoporosis International (2011, March), 22(Suppl.1), 291-292 Detailed reference viewed: 72 (4 ULg) Five-year Denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension; ; et al in Osteoporosis International (2011, March), 22(Suppl.1), 107-108 Detailed reference viewed: 91 (6 ULg) Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.; ; et al in Calcified Tissue International (2011), 88(6), 485-94 Vitamin D insufficiency is common in patients with osteoporosis. We conducted a randomized trial comparing alendronate 70 mg combined with vitamin D(3) 5,600 IU in a single tablet (ALN/D5600, n = 257 ... [more ▼] Vitamin D insufficiency is common in patients with osteoporosis. We conducted a randomized trial comparing alendronate 70 mg combined with vitamin D(3) 5,600 IU in a single tablet (ALN/D5600, n = 257) with standard care chosen by the patients' personal physicians (n = 258) in patients with postmenopausal osteoporosis (BMD T score </=2.5 or </=1.5 and a prior fragility fracture) who had vitamin D insufficiency (serum 25[OH]D values 8-20 ng/ml) and who were at risk of falls. Virtually all patients randomized to standard care received bisphosphonate therapy, and in approximately 70% of cases this was combined with vitamin D supplements. However, only 24% took >/=800 IU/day of supplemental vitamin D. At 6 months the proportion of patients with vitamin D insufficiency was 8.6% in the ALN/D5600 group compared with 31.0% in the standard care group (P < 0.001). Those in the ALN/D5600 group also had a greater reduction in urinary NTX/creatinine ratio (-57% vs. -46%, P < 0.001) and bone-specific alkaline phosphatase (-47% vs. -40%, P < 0.001). In the ALN/5600 group, by 12 months the increase in BMD was greater at the lumbar spine (4.9% vs. 3.9%, P = 0.047) and the total hip (2.2% vs. 1.4%, P = 0.035), significantly fewer patients were vitamin D-insufficient (11.3% vs. 36.9%, P < 0.001), and bone turnover marker (BTM) results were similar to those at 6 months. There was no difference between groups in those who experienced falls or fractures, and adverse events were similar. Based on the finding that ALN/D5600 was more effective than standard care at correcting vitamin D insufficiency, increasing BMD, and reducing BTMs in this patient group, greater attention needs to be directed toward optimizing the treatment of osteoporosis and correcting vitamin D deficiency in postmenopausal women. [less ▲] Detailed reference viewed: 18 (2 ULg) Ranélate de strontium : efficacité à long terme sur 10 ans chez les femmes ménopausées ostéoporotiquesReginster, Jean-Yves ; ; et alin Revue du Rhumatisme (2010, November), 77(Suppl.3), 99-100 Detailed reference viewed: 6 (0 ULg) Building and tracking root shapes.; Schwartz, Cédric ; et alin IEEE Transactions on Biomedical Engineering (2010), 57(3), 696-707 An algorithm aiming at robust and simultaneous registrations of a sequence of 3-D shapes was recently presented by Jacq et al. [IEEE Trans. Biomed. Eng., vol. 55, no. 5, 2008]. This algorithm has to carry ... [more ▼] An algorithm aiming at robust and simultaneous registrations of a sequence of 3-D shapes was recently presented by Jacq et al. [IEEE Trans. Biomed. Eng., vol. 55, no. 5, 2008]. This algorithm has to carry out an implicit representation of their common root shape (RS). A particular emphasis was put on the median consensus shape, which is a specific type of RS. Unlike this previous study, mainly focusing on the algorithm foundations while dealing with very specific applications examples, this paper attempts to show the versatility of the RS concept through a set of three problems involving a wider scope of application. The first problem copes with the design of prosthetic cortical plates for the hip joint. It shows how an explicit reconstruction of the RS, coming with its consensus map, could bring out an intermediary anatomical support from which pragmatic choices could be made, thereby performing a tradeoff between morphological, surgical, and production considerations. The second problem addresses in vivo real-time shoulder biomechanics through a miniature 3-D video camera. This new protocol implicitly operates through RS tracking of the content of virtual spotlights. It is shown that the current medical-oriented protocol, while operating within expert offices through low-cost equipments, could challenge high-end professional equipments despite some limitations of the 3-D video cameras currently available. The last problem deals with respiratory motions. This is an auxiliary measurement required by some medical imaging systems that can be handled as a basic application case of the former new protocol. [less ▲] Detailed reference viewed: 30 (8 ULg) Effect of single annual infusion of zoledronic acid on bone turnover markers versus daily oral risedronate in patients with glucocorticoid-induced osteoporosis; ; et al in Osteoporosis International (2009, April), 20(Suppl.1), 128-129 Detailed reference viewed: 9 (4 ULg) Effect on single annual infusion of zoledronic acid (5mg) on lumbar spine bone mineral density versus daily oral risedronate (5mg) in subgroups of patients receiving glucocorticoid therapy.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 7-8 Detailed reference viewed: 7 (1 ULg) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.; ; et al in Lancet (2009), 373(9671), 1253-63 BACKGROUND: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral ... [more ▼] BACKGROUND: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compliance and adherence. We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. METHODS: This 1-year randomised, double-blind, double-dummy, non-inferiority study of 54 centres in 12 European countries, Australia, Hong Kong, Israel, and the USA, tested the effectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. 833 patients were randomised 1:1 to receive zoledronic acid (n=416) or risedronate (n=417). Patients were stratified by sex, and allocated to prevention or treatment subgroups dependent on duration of glucocorticoid use immediately preceding the study. The treatment subgroup consisted of those treated for more than 3 months (272 patients on zoledronic acid and 273 on risedronate), and the prevention subgroup of those treated for less than 3 months (144 patients on each drug). 62 patients did not complete the study because of adverse events, withdrawal of consent, loss to follow-up, death, misrandomisation, or protocol deviation. The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a modified intention-to-treat basis and safety was assessed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00100620. FINDINGS: Zoledronic acid was non-inferior and superior to risedronate for increase of lumbar spine bone mineral density in both the treatment (least-squares mean 4.06% [SE 0.28] vs 2.71% [SE 0.28], mean difference 1.36% [95% CI 0.67-2.05], p=0.0001) and prevention (2.60% [0.45] vs 0.64% [0.46], 1.96% [1.04-2.88], p<0.0001) subgroups at 12 months. Adverse events were more frequent in patients given zoledronic acid than in those on risedronate, largely as a result of transient symptoms during the first 3 days after infusion. Serious adverse events were worsening rheumatoid arthritis for the treatment subgroup and pyrexia for the prevention subgroup. INTERPRETATION: A single 5 mg intravenous infusion of zoledronic acid is non-inferior, possibly more effective, and more acceptable to patients than is 5 mg of oral risedronate daily for prevention and treatment of bone loss that is associated with glucocorticoid use. [less ▲] Detailed reference viewed: 307 (2 ULg) A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis; ; et al in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 56 Detailed reference viewed: 10 (2 ULg) A single infusion of zoledronic acid 5 mg (ZOL) is significantly more effective than daily oral risedronate 5 mg (RIS) in increasing bone mineral density (BMD) of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (GIO); ; et al in Osteoporosis International (2008, April), 19(Suppl.1), 23-24 Detailed reference viewed: 16 (1 ULg) Relationship between Change in Femoral Neck Bone Mineral Density and Hip Fracture Incidence During Treatment with Strontium RanelateBruyère, Olivier ; ; et alin Current Medical Research & Opinion (2007), 23(12), 3041-5 OBJECTIVE: Strontium ranelate (SR) increases bone mineral density (BMD) in postmenopausal osteoporotic women and reduces vertebral and non-vertebral fracture incidence. Hip fracture reduction has also ... [more ▼] OBJECTIVE: Strontium ranelate (SR) increases bone mineral density (BMD) in postmenopausal osteoporotic women and reduces vertebral and non-vertebral fracture incidence. Hip fracture reduction has also been observed during 3-year treatment with SR in osteoporotic women at high risk of hip fracture. The objective of this study is to analyse the association between BMD changes and hip fracture incidence during treatment with SR. MATERIAL AND METHODS: In this post-hoc analysis, 465 women aged over 74 years with low BMD at the femoral neck (T-score < or = -2.4 according to NHANES normative values) were selected from the population of a recently published study (the Treatment of Peripheral Osteoporosis Study - TROPOS). BMD was assessed at the femoral neck at baseline and after a follow-up of 3 years. Hip fractures were reported by study investigators. RESULTS: After adjusting for age, body mass index, femoral neck BMD at baseline and number of prevalent vertebral fractures, we found that for each 1% increase in femoral neck BMD observed after 3 years, the risk to experience a hip fracture after 3 years decreased by 7% (95% CI: 1-14%) (p = 0.04). In patients experiencing a hip fracture over 3 years of treatment with SR, femoral neck BMD increased by (mean [SE]) 3.41 (1.02)% compared to 7.23 (0.81)% in patients without hip fracture (p = 0.02). CONCLUSION: In this post-hoc analysis of women undergoing 3 years of SR treatment, an increase in femoral neck BMD is associated with a decrease in hip fracture incidence. [less ▲] Detailed reference viewed: 38 (8 ULg) Effects of strontium ranelate on radiographic spinal osteoarthritis progressionBruyère, Olivier ; ; et alin Arthritis and Rheumatism (2007, September), 56(number 9 (suppl.)), 315 Detailed reference viewed: 11 (4 ULg) Increase in femoral neck bone mineral density is associated with decrease in vertebral and hip fracture incidence during a 3-year treatment with strontium ranelateBruyère, Olivier ; ; Detilleux, Johann et alin Annals of the Rheumatic Diseases (2007, June), 66(Suppl.II), 521 Detailed reference viewed: 6 (3 ULg) Strontium ranelate decreases vertebral fracture risk whatever the level of pretreatment bone turnover markersCOLLETTE, Julien ; Reginster, Jean-Yves ; Bruyère, Olivier et alin Calcified Tissue International (2007, May), 80(Suppl.1), 29-30 Detailed reference viewed: 8 (1 ULg) Effect of age on a fractal bone texture parameter assessed by high resolution digital X Ray: a multicenter pilot study; ; et al in Osteoporosis International (2007, March), 18(Suppl.1), 102 Detailed reference viewed: 12 (2 ULg) |
||